Tribun Health Awarded Over €600K For Pathomix Digital Pathology Project

Tribun Health, a leading provider of software solutions for digital pathology, has recently been honored as one of the winners in the i-Nov Wave 11 competition, an initiative by Bpifrance under the France 2030 plan. The competition is designed to foster the rapid development of innovative companies that are setting standards in their respective industries. Tribun Health's flagship image management software, CaloPix®, has been recognized for its transformative impact on anatomopathology, offering a digital substitute to conventional microscopes and modernizing the diagnostic process for medical professionals.

The company's ambitious project, "Pathomix®," aims to expand its diagnostic product range, enhancing the integration between healthcare services and the latest research and pharmaceutical developments. This initiative is set to revolutionize pathology's contribution to precision medicine by providing sophisticated tools for the consolidation, improvement, and utilization of real-world data. Central to Pathomix® is the creation of an advanced data query module that enables healthcare facilities to identify specific data for secondary use while complying with GDPR and HIPAA regulations. The primary objective is to achieve data interoperability and facilitate smoother interactions among CaloPix® users, mainly pathologists, and stakeholders in multicenter research and development projects.

Bertrand de Fürst, Innovation Director at Tribun Health, expressed gratitude for the French public actors' support, emphasizing it as a testament to their confidence in Tribun Health's dedication to enhancing modern medicine and its accessibility. "Digitization in anatomy and pathological cytology is pivotal for making informed therapeutic decisions and understanding diseases. Our Pathomix® project is geared towards automating the extraction and export of histopathological and clinical data from real-life patient cases for research purposes," he stated.

Jean-François Pomerol, CEO of Tribun Health, highlighted the project's significance in meeting the demands of pharmaceutical laboratories and AI companies by facilitating the assembly of uniform cohorts crucial for precision medicine initiatives. "Our technology is designed to efficiently respond to data inquiries and expand research archives, thereby promoting advancements in healthcare research and innovation," Pomerol added.

The i-Nov jury selected Tribun Health’s Pathomix® project under the "Health" theme, awarding it substantial financial support amounting to €618,000, comprising both a grant and repayable advances. This accolade, along with the FrenchTech 2030 label received in 2023, reinforces Tribun Health's dominant position in the market amidst intense global competition and underscores the importance of investing in innovation.